You are here

  • Home
  • Archive
  • Volume 94, Issue 1
  • Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Article metrics

Article menu

Download PDFPDF

Multiple sclerosis
Original research
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2024

AbstractFullPdf
Nov 2022803534145
Dec 2022830767203
Jan 2023580542235
Feb 2023445440188
Mar 2023293285124
Apr 2023251232114
May 2023271252104
Jun 202321320194
Jul 202326926081
Aug 202324322265
Sep 202317015150
Oct 202320318269
Nov 202321819970
Dec 202319316373
Jan 202417914545
Feb 202410910340
Mar 20241069990
Total537647771790